FDA Proposes Removal of Oral Phenylephrine as Ineffective Nasal Decongestant
核心洞察
The FDA is proposing to remove oral phenylephrine from over-the-counter (OTC) cold medications, deeming it ineffective as a nasal decongestant.
This decision follows a review of available data, including historical data and recent studies, which showed phenylephrine was no more effective than a placebo.
The move is influenced by research dating back to the 1970s and petitions from pharmacists who questioned phenylephrine's efficacy, leading to advisory committee meetings.
The Food and Drug Administration (FDA) has proposed that nonprescription drugs containing oral phenylephrine should be removed from pharmacy shelves, citing its ineffectiveness as a nasal decongestant. This proposal could significantly alter the landscape of over-the-counter (OTC) cold medications, impacting products like Mucinex and Sudafed PE.
Efficacy Concerns
According to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER), this action is based on a thorough review of available data, aligning with the advice of an advisory committee. The review included historical data used to initially support phenylephrine's effectiveness 30 years ago.
Research questioning the efficacy of phenylephrine has been ongoing for many years. An article published in 1993, based on research from the 1970s, suggested that while phenylpropanolamine and pseudoephedrine were effective decongestants, oral phenylephrine was not. More recently, a 2023 review in Cureus found that oral phenylephrine was not significantly more effective than a placebo in alleviating nasal congestion in adults. This systematic review analyzed multiple studies comparing oral phenylephrine to placebo or standard care, assessing their impact on congestion and nasal airway resistance.
The Path to Review
The FDA's reevaluation was spurred by the work of Randy C. Hatton, Pharm.D., and Leslie Hendeles, Pharm.D., from the University of Florida College of Pharmacy. Their research, initiated in 2005, led to two petitions urging the FDA to review the evidence. This culminated in two FDA advisory committee meetings, the most recent in October 2023, where all 16 members voted against the assertion that orally administered phenylephrine is effective as a nasal decongestant.
Historical Context
Phenylephrine's widespread use in nonprescription cold medications increased after 2006, when products containing pseudoephedrine were moved behind pharmacy counters due to its potential use in methamphetamine production. Manufacturers reformulated many cold products with phenylephrine as a substitute.
In a Scientific American article, Hatton highlighted that phenylephrine was initially approved before the 1962 Kefauver-Harris Amendments, which established rigorous clinical trial standards for drug approval. This meant that phenylephrine's initial approval did not require proof of efficacy, relying instead on chemistry studies to demonstrate safety. The FDA established the OTC monograph process 10 years after the 1962 amendment to reconsider products that hadn't been proven effective.
Next Steps
For now, products containing phenylephrine remain available to consumers. The FDA is soliciting public comments on the proposed order until May 7, 2025, after which it will issue a final decision regarding the future of oral phenylephrine in OTC medications.